Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. https://www.medrxiv.org/content/10.1101/2023.07.11.23292344
Latent EBV impairs immune cell signaling and enhances the efficacy of anti-CD3 mAb in Type 1 Diabetes. https://www.medrxiv.org/content/10.1101/2023.07.11.23292344